In rare cases, fatigue may increase during therapy. In this case, the therapy should not be discontinued and the recommended dose should not be exceeded. If, during maintenance treatment, the therapeutic effects wane, the treatment should also be discontinued.
Treatment with Frego may give rise to extrapyramidal and depressive symptoms and reveal parkinsonism, especially in predisposed patients eg, elderly. Therefore, it should be used with caution in such patients.
Patients should be seen at regular intervals, especially during maintenance treatment, so that extrapyramidal or depressive symptoms may be detected early, and if so, treatment discontinued.
Caution should also be taken in hypotensive patients.
Use with caution in patients with renal failure.
Liver and renal function should be monitored during the long period of treatment.
Effects on the Ability to Drive or Operate Machinery: Frego causes drowsiness and since somnolence may occur especially at the start of the treatment, Frego should not be given to patients doing activities ie, driving or operating machinery.
Use in pregnancy & lactation: Frego is not recommended for pregnant women since safety has not been established.
Flunarizine is excreted in breast milk, therefore, Frego should not be given to breastfeeding women.
Use in the elderly: Use with caution in elderly patients.